N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

NCT07217496 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Business decision

Conditions

Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Locally Advanced Urothelial Carcinoma
Urothelial Cancer

Interventions

DRUG: Nogapendekin Alfa Inbakicept (N803)
DRUG: Enfortumab Vedotin (EV)
DRUG: Pembrolizumab
PROCEDURE: Research Biospecimen Collection
PROCEDURE: Radiographic Imaging
PROCEDURE: Tumor Biopsy

Sponsor

Vadim S Koshkin

Collaborators

[object Object]